Disclosures to IC. Prior to execution of this CRADA, Collaborator agrees to disclose to IC all instances in which outstanding royalties are due under a PHS license agreement and in which Collaborator had a PHS license terminated in accordance with 37 C.F.R. § 404.10. These disclosures will be treated as Confidential Information upon request by Collaborator in accordance with the definition in Article 2 and Paragraphs 8.3 and 8.4.
Appears in 14 contracts
Samples: Cooperative Research and Development Agreement (Curative Biotechnology Inc), Cooperative Research and Development Agreement, Cooperative Research and Development Agreement (Ziopharm Oncology Inc)
Disclosures to IC. Prior to execution of this CRADA, Collaborator agrees to disclose to IC all instances in which outstanding royalties are due under a PHS license agreement agreement, and in which Collaborator had a PHS license terminated in accordance with 37 C.F.R. § 404.10. These disclosures will be treated as Confidential Information upon request by Collaborator in accordance with the definition in Article 2 and Paragraphs 8.3 2.4, 8.3, and 8.4.
Appears in 6 contracts
Samples: Cooperative Research and Development Agreement (BriaCell Therapeutics Corp.), Cooperative Research and Development Agreement (Virpax Pharmaceuticals, Inc.), Cooperative Research and Development Agreement (Scopus BioPharma Inc.)
Disclosures to IC. Prior to execution of this CRADA, Collaborator agrees to disclose to IC all instances in which outstanding royalties are due under a PHS an NIH license agreement and in which Collaborator had a PHS an NIH license terminated in accordance with 37 C.F.R. § 404.10. These disclosures will be treated as Confidential Information upon request by Collaborator in accordance with the definition in Article 2 and Paragraphs 8.3 and 8.4.
Appears in 1 contract
Disclosures to IC. Prior to execution of this CRADA, Collaborator agrees to disclose to IC all instances in which outstanding royalties are due under a PHS license agreement and in which Collaborator had a PHS license terminated in accordance with 37 C.F.R. § 404.10. These disclosures will be treated as Collaborator Confidential Information upon request by Collaborator in accordance with the definition in Article 2 and Paragraphs 8.3 and 8.4.
Appears in 1 contract
Samples: Cooperative Research and Development Agreement (Exelixis, Inc.)